The Athens Stock Exchange managed to stay within striking distance of the 1,450 level today (3/9), with selective placements absorbing the increasing exogenous pressures.
Indeed, the Greek market, having made a satisfactory "bounce" in September, maintained its relatively autonomous course against the international stock markets, which continue to be on a downward trend in anticipation of the critical macroeconomic data in the US.
Specifically, in the second session of the week, the General Index was almost unchanged (-0.01%) at 1,446.09 points, the same as Monday's close (1,446.17 points).
The arc of daily fluctuations was fixed at six points (from 1,444.48 to 1,450.42 points), with a turnover of 85 million euros, of which 19.4 million euros related to pre-agreed packages.
The banking index not only did not try to approach the 1,300 points zone, but eventually ended up -0.64% and 1,274 points, negatively affecting the market as a whole.
Piraeus shares fell to -0.92% and EUR 3.983, National Bank shares retreated to -1.08% and EUR 7.892, Eurobank shares traded at -0.68% and EUR 2.05, while Alpha shares rose to +0.19% and EUR 1.579.
Sarantis shares rose +4.4% and 10.7 euros in the high-cap index (-0.24% and 3,511 points), helped by improved semi-annual profitability. Motor Oil and Autohellas followed at +2%, while Lamda, Aegean (announced investment in Volotea) and EYDAP closed +1%. On the flip side, Cenergy's shares were down 1.6%, with OTE following at -1.1%. Shares of OPAP, which will announce its Q2 results and 2024 interim dividend today, fell 0.3% but defended the €16 level.
As for the mid-cap index (+1.05% and 2,337 points), ADMIE shares stood out at +4.4% and 2.21 euros (one-month high), thanks to the looming agreement on the Crete-Cyprus electricity link. The shares of EXAE also gained 2.6%. At the same time, shares of PPA, Kri Kri, Intracom, EYATH, AVAX, and Profile rose more than +1%. On the contrary, the shares of Austriacard lost 1.6%.
A special mention should be made of Attica Bank, as the approval to the merger plan with Pancreta led to +18% and EUR 9.8.
